Only in Titles

Search results for: Anti human Antithrombin Whole IgG from antiserum


Error loading info... Pleas try again later.

#22542931   2012/04/20 To Up

Interference of thrombin in immunological assays for hirudin specific antibodies.

Recombinant hirudins (desirudin, lepirudin) are direct thrombin inhibitors administered as anticoagulants for heparin-induced thrombocytopenia (HIT) and venous thromboembolism (VTE) prophylaxis. Although these small polypeptides are widely used, concern exists over reports of antigenicity. In the largest study of r-hirudin immunogenicity to-date, we evaluated the prevalence, quantity and specificity of IgG immune responses to desirudin (15 mg SC q12h for as long as clinically required) in 245 surgical and medically-ill subjects enrolled in DESIRABLE, a multicenter, open-label, clinical trial of hospitalized patients requiring VTE prophylaxis. Sera obtained before and 30 days after desirudin administration were analyzed for IgG anti-desirudin by immunoenzymetric assay using immobilized desirudin to bind desirudin-reactive antibody and peroxidase conjugated monoclonal-anti-human IgG Fc to detect bound IgG antibody. Of 245 study subjects, 19 (7.7%) were antibody "responders" (>2-fold increase in IgG antibody levels with >50% inhibition by desirudin 30 days post-treatment). There were no differences between responders and non-responders in incidence of clinical outcomes or bleeding-related adverse events. Forty-six patients had detectable desirudin-reactive IgG antibody prior to treatment, with no significant increase in antibody levels after exposure and no increase in clinical events. The origin of pre-existing hirudin-reactive IgG antibody requires further investigation involving suspected anti-thrombin-thrombin interactions. These results indicate a low potential for immunogenicity, with <8% of patients developing IgG antibodies after desirudin administration for VTE prophylaxis. In contrast to reports on lepirudin, production of anti-hirudin antibodies to desirudin has no apparent effect on clinical events.
Robert G Hamilton, Jerrold H Levy, Victor J Marder, David C Sane

1138 related Products with: Interference of thrombin in immunological assays for hirudin specific antibodies.

4 Membranes/Box2 Pieces/Box4 Arrays/Slide4 Membranes/Box2 Pieces/Box2 Pieces/Box4 Membranes/Box2 Pieces/Box4 Arrays/Slide4 Membranes/Box4 Membranes/Box2 Pieces/Box

Related Pathways


#7974394   // To Up

The effect of plasma antithrombin concentration on thrombin generation and fibrin gel structure.

Congenital deficiency of antithrombin (AT) is associated with thrombotic events and AT consumption occurs in some severe disorders and after treatment with heparin. The aim of this study was to investigate whether variations in the level of plasma AT modify thrombin generation and the fibrin formation process after the intrinsic coagulation mechanism is triggered. Normal plasma was depleted of AT by immunoadsorption on CNBr-Sepharose coupled with the anti-AT-IgG fraction of antiserum. The AT-depleted plasma was reconstituted with AT (between 0.3 and 1.5 AT units per ml). Thrombin generation was measured as the development of thrombin-antithrombin complexes (TAT). The lag phase preceding fibrin formation depended on the concentration of AT. The short lag phase was seen in completely AT-depleted plasma and the long in plasma with 1.5 AT units per ml. TAT generation, determined in parallel consecutive samples, showed that the rate at which thrombin was generated was inverse to the AT concentration in plasma. The network structure of hydrated fibrin gels in the clotted plasma was studied by measuring the wavelength dependence of gel turbidity. The mass/length ratio value, -i.e. the thickness of fiber strands and porosity of the gel increased with increasing AT concentrations. It is concluded that plasma AT regulates the rate of prothrombin-thrombin conversion, the clotting time and the consequently network structure of the fibrin gel.
G Elgue, J Sanchez, K Fatah, P Olsson, B Blombäck

2247 related Products with: The effect of plasma antithrombin concentration on thrombin generation and fibrin gel structure.

96T96T1.0mg1 Gram100 mg500 ml1 kit(96 Wells)

Related Pathways


#2340307   // To Up

Rapid and simple isolation procedure for lipoprotein lipase from human milk.

Lipoprotein lipase (LPL) is an important enzyme in lipid and energy metabolism of all vertebrates. Measurement of its activity in human postheparin plasma has become a standard procedure for diagnosis of Type I hyperlipoproteinemia and other types of hypertriglyceridemias. This paper presents a rapid and simple purification procedure for human lipoprotein lipase and the production of specific polyclonal antibodies. In the isolation procedure, the fat moiety of human milk obtained by centrifugation was delipidated and a buffer-extractable fraction chromatographed sequentially on heparin-Sepharose and phenyl-Sepharose. This three-step procedure provides a high yield of apparently pure LPL with very high specific activity against radiolabeled triacylglycerol substrates. The apparent molecular weight of LPL on SDS-PAGE was 60 kDa. Amino acid analysis and NH2-terminal sequencing proved the identity and the apparent homogeneity of the isolated enzyme. alpha-Lactoferrin and antithrombin III, common contaminants in earlier isolation procedures, were not detectable immunologically. Purified LPL was used to produce in the rabbit a specific polyclonal antiserum that inhibited LPL activity from human postheparin plasma and other tissues. In postheparin plasma from normal individuals, anti-LPL IgG was used in Western blotting to show LPL protein. In preheparin plasma, or in certain patients with Type I hyperlipoproteinemia, no specific signal was detected. The improved purification procedure presented here allows the rapid isolation of human LPL and production of antibodies to the protein, both of which will greatly facilitate future studies of this important enzyme.
R Zechner

1031 related Products with: Rapid and simple isolation procedure for lipoprotein lipase from human milk.

0.1 mg0.1 mg1 mg400Tests20 ug200 0.1 mg10 200 500 10ìg1 mg

Related Pathways


#3932464   // To Up

Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma.

A novel platelet-agglutinating protein (PAP) was purified approximately 2,000-fold from the plasma of a patient with thrombotic thrombocytopenic purpura (TTP) by ammonium sulfate fractionation, DEAE-Sephacel and concanavalin A-Sepharose chromatographies. On sodium dodecyl sulfate-polyacrylamide gel electrophoresis, with and without reduction, this preparation revealed a major protein band with a molecular weight of 37,000, and a minor band with a molecular weight of 32,000-34,000. After elution from the gel, only the 37,000-mol wt protein corresponding to the major band induced the platelet agglutination. When four normal plasmas and the recovery plasma from the same TTP patient were subjected to the similar purification steps, the 37,000-mol wt major band was absent. The 125I-PAP bound to the platelets in a concentration-dependent manner. The platelet agglutination induced by PAP was not inhibited by hirudin, heparin in the presence of antithrombin III, phenylmethylsulfonyl fluoride, apyrase, aspirin, or prostaglandin I2. However, it was inhibited by IgG from normal adults and from the same TTP patient after recovery. The anti-37,000-mol wt PAP antiserum prepared in the rabbit formed a single precipitin line against the highly purified PAP. Using this antiserum in the Western immunoblotting, the 37,000-mol wt protein band was found in the three TTP plasmas, of which the platelet-agglutinating activity was inhibited by the anti-37,000-mol wt PAP IgG. The 37,000-mol wt immunoprecipitin band was absent in the plasmas obtained from another two TTP patients, two normal subjects, two patients with idiopathic thrombocytopenic purpura, and two patients with disseminated intravascular coagulation. These results suggest that the 37,000-mol wt PAP is present only in certain cases of TTP, and is likely to be responsible for the formation of platelet thrombi in the microcirculation.
F A Siddiqui, E C Lian

2173 related Products with: Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma.

1.0mg96T1mg0.05 mg96T 50 UG1.0mg100ug100ug100ug Lyophilized1 Set100ug Lyophilized

Related Pathways


#58955   // To Up

alpha2-Macroglobulin on human vascular endothelium.

alpha2-Macroglobulin (alpha2M) has been identified on the luminal surface of endothelial cells in sections of normal human arteries, veins, and lymphatics by the indirect immunofluorescent technique. The specificity of the immunofluorescent reaction was confirmed by immunoabsorption studies. Prior absorption of the anti-alpha2M antiserum by purified alpha2M at equivalence completely inhibited endothelial surface as well as hepatic parenchymal cell staining. Endothelial cells in blood vessels were not stained when sections were treated with rabbit antisera toward alpha1-antitrypsin, antithrombin III, IgG, IgA, IgM, C3, or fibrinogen. The location of alpha2M at the surface of the vessel wall suggests that this protease inhibitor may protect the vascular endothelium from potentially injurious intravascular proteases.
C G Becker, P C Harpel

1766 related Products with: alpha2-Macroglobulin on human vascular endothelium.

100ul96tests2 2ug1 ml2ug1 mg100.00 ug10 μg100.00 ug100 μg 100ul

Related Pathways